References

  1. 1. YUPELRI [package insert]. Morgantown, WV: Mylan Specialty LP.
  2. 2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD: 2024 report. Global Initiative for Chronic Obstructive Lung Disease, Inc. Accessed October 21, 2024. https://goldcopd.org/2024-gold-report/
  3. 3. Gardenhire DS, Burnett D, Strickland S, Myers TR. A guide to aerosol delivery devices for respiratory therapists. 4th ed. Irving, TX: American Association for Respiratory Care; 2017.
  4. 4. Nebulizers—Policy Article. Centers for Medicare & Medicaid Services website. Published October 1, 2015. Updated January 1, 2024. Accessed October 21, 2024. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=52466
  5. 5. Sulaiman I, Cushen B, Greene G, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(10):1333-1343.
  6. 6. Schure MB, Borson S, Nguyen HQ, et al. Associations of cognition with physical functioning and health-related quality of life among COPD patients. Respir Med. 2016;114:46-52.
  7. 7. Baird C, Lovell J, Johnson M, et al. The impact of cognitive impairment on self-management in chronic obstructive pulmonary disease: a systematic review. Respir Med. 2017;129:130-139.
  8. 8. Hanania NA, Braman S, Adams SG, et al. The role of inhalation delivery devices in COPD: perspectives of patients and health care providers. Chronic Obstr Pulm Dis. 2018;5(2):111-123.
  9. 9. Wise RA, Acevedo RA, Anzueto AR, et al. Guiding principles for the use of nebulized long-acting beta2-agonists in patients with COPD: an expert panel consensus. Chronic Obstr Pulm Dis. 2016;4(1):7-20.
  10. 10. Celli BR, Navaie M, Xu Z, et al. Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment. Int J Chron Obstruct Pulmon Dis. 2019;14:1019-1031.
  11. 11. Diette GB, Dalal AA, D Souza AO, et al. Treatment patterns of chronic obstructive pulmonary disease in employed adults in the United States. Int J Chron Obstruct Pulmon Dis. 2015;10:415-422.
  12. 12. Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2013;26(3):174-179.
  13. 13. Bosnic-Anticevich S, Chrystyn H, Costello RW, et al. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. Int J Chron Obstruct Pulmon Dis. 2016;12:59-71.
  14. 14. Sharma G, Mahler DA, Mayorga VM, et al. Prevalence of low peak inspiratory flow rate at discharge in patients hospitalized for COPD exacerbation. Chronic Obstr Pulm Dis. 2017;4(3):217-224.
  15. 15. Dhand R, Dolovich M, Chipps B, et al. The role of nebulized therapy in the management of COPD: evidence and recommendations. COPD. 2012;9(1):58-72.
  16. 16. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet. 2011;377(9770):1032-1045.
  17. 17. Ibrahim M, Verma R, Garcia-Contreras L. Inhalation drug delivery devices: technology update. Med Devices (Auckl). 2015;8:131-139.
  18. 18. Martin AR, Finlay WH. Nebulizers for drug delivery to the lungs. Expert Opin Drug Deliv. 2015;12(6):889-900.
  19. 19. De Vries M, Garner S, Hartley C, Stocking J. Pulmonary disease aerosol delivery devices: a guide for physicians, nurses, pharmacists, and other health care professionals, 4th ed. American Association for Respiratory Care. Accessed December 4, 2024. https://www.aarc.org/wp-content/uploads/2023/06/aerosol_guide_for_HCPs_4th_ed.pdf
  20. 20. Goldman RE, Mennillo L, Stebbins P, et al. How do patients conceptualize chronic obstructive pulmonary disease? Chron Respir Dis. 2017:14(3);245-255.
  21. 21. Sigurgeirsdottir J, Halldorsdottir S, Arnardottir RH, et al. Frustrated caring: Family members' experience of motivating COPD patients towards self-management. Int J Chron Obstruct Pulmon Dis. 2020;15:2953-2965.
  22. 22. Berger BE, Kapella MC, Larson JL. The experience of stigma in chronic obstructive pulmonary disease. West J Nurs Res. 2011;33(7):916-932.
  23. 23. Johnson JL, Campbell AC, Bowers M, et al. Understanding the social consequences of chronic obstructive pulmonary disease: the effects of stigma and gender. Proc Am Thorac Soc. 2007;4(8):680-682.
  24. 24. Taber JM, Leyva B, Persoskie A. Why do people avoid medical care? A qualitative study using national data. J Gen Intern Med. 2015;30(3):290-297.
  25. 25. Data on file. Mylan Specialty LP, a Viatris Company.
  26. 26. Pudi KK, Barnes CN, Moran EJ, et al. A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. Respir Res. 2017;18(1):182.
  27. 27. St. George's Respiratory Questionnaire. American Thoracic Society website. Accessed October 21, 2024. https://www.thoracic.org/members/assemblies/assemblies/srn/questionaires/sgrq.php
  28. 28. Long-acting medication use in COPD: opportunities for minimizing medication waste in the hospital setting. Pharm Times. November 2017. Accessed October 21, 2024. https://pharmacytimes.s3.amazonaws.com/v1_media/RESP242-17-%20Pharmacy%20Times%20Unused%20Canister%20White%20Paper_FINAL.pdf
  29. 29. Costs. Medicare.gov. Accessed October 21, 2024. https://www.medicare.gov/basics/costs/medicare-costs
  30. 30. Centers for Medicare & Medicaid Services. MLN Matters. Number MM8304. Accessed October 21, 2024. https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2013-Transmittals-Items/R468PI
  31. 31. Centers for Medicare & Medicaid Services. Medicare claims processing manual. Chapter 17—drugs and biologicals (rev. 12511; issued 2-15-24). Accessed October 21, 2024. https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c17.pdf